:: Library Catalog

Cover Image

Saved in:

Bibliographic Details
Main Author:	Iskandar Idris
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Diabetes, Obesity and Metabolism Now
Online Access:	https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1002/doi2.93
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Can diet and exercise intervention prevent type 2 diabetes in individuals with a high genetic risk?
by: Iskandar Idris
Published: (2024)

Precision medicine approach to detect obese people who are at high risk of developing diabetes
by: Iskandar Idris
Published: (2024)

Epigenetic changes shown to cause type 2 diabetes
by: Iskandar Idris
Published: (2024)

Hybrid closed‐loop therapy significantly improved maternal glucose control during pregnancy complicated by type 1 diabetes
by: Iskandar Idris
Published: (2024)

Extension study from DIRECT showed ongoing remission rate from type 2 diabetes in some patient following very low calorie diet at 5 years
by: Iskandar Idris
Published: (2024)

Glucagon like peptide‐1 (GLP‐1) therapy is associated with reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes with chronic liver disease
by: Iskandar Idris
Published: (2024)

Adults who are overweight or obese may experience greater pain intensity compared with normal weight individuals?
by: Iskandar Idris
Published: (2024)

Tirzepatide shown to improve clinical outcomes for patients with heart failure with preserved ejection fraction (HFpEF) and obesity
by: Iskandar Idris
Published: (2024)

Fenofibrate shown to reduce progression of diabetic retinopathy
by: Iskandar Idris
Published: (2024)

The glucagon like peptide‐1 linked to nonarteritic anterior ischemic optic neuropathy
by: Iskandar Idris
Published: (2024)

Potential role of glucagon like peptide (GLP)‐1 receptor agonist to reduce risk of colorectal cancer?
by: Iskandar Idris
Published: (2024)

Tirzepatide shown to be effective at reducing sleep disturbances in patients with obstructive sleep apnoea
by: Iskandar Idris
Published: (2024)

The US Food and Drug administration has approved resmetirom as the first drug to treat metabolic dysfunction‐associated steatohepatitis (MASH)
by: Iskandar Idris
Published: (2024)

Potential new therapies to preserve lean muscle mass loss when used in combination with glucagon‐like peptide 1 (GLP‐1) receptor agonist being studied
by: Iskandar Idris
Published: (2024)

Real world study provided reassurance of the safety of GLP‐1 therapy on mental health and suicide risk
by: Iskandar Idris
Published: (2024)

Real world data showed that the dual GLP gip agonist, Tirzepatide is associated with lower mortality, cardiovascular events and adverse kidney events compared with GLP‐1 analogue
by: Iskandar Idris
Published: (2024)

Increased expression of the protein Kallistatin after weight loss induces beneficial metabolic effects: A potential new therapeutic target?
by: Iskandar Idris
Published: (2024)

Increasing excess to weight loss injection shown to save thousands of lives a year
by: Iskandar Idris
Published: (2024)

Issue Information
Published: (2024)

Issue Information
Published: (2024)

Issue Information
Published: (2024)

Issue Information
Published: (2024)

Issue Information
Published: (2024)

Issue Information
Published: (2024)

Issue Information
Published: (2024)

Issue Information
Published: (2024)

The latest evidence and guidance in lifestyle and surgical interventions to achieve weight loss in people with overweight or obesity
by: Iskandar Idris, et al.
Published: (2025)

Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity
by: Jonathan Brix Winther, et al.
Published: (2024)

Prevalence of obesity and cardiovascular disease in adults with type 2 diabetes and use of diabetes medication in Germany: A claims data study
by: Nora Hennies, et al.
Published: (2024)

Practical strategies to manage obesity in type 2 diabetes
by: Helena W. Rodbard, et al.
Published: (2024)

Association between time in tight range and incident diabetic retinopathy in adults with type 2 diabetes
by: Yaxin Wang, et al.
Published: (2024)

Post‐exercise glycaemic control for 24 h: Fasted morning exercise with and without glucagon in adults with type 1 diabetes using automated insulin delivery
by: Clara Solà, et al.
Published: (2025)

Glycaemic impact of the pre‐exercise timing of an elevated glucose target implemented using an automated insulin delivery system in adults with type 1 diabetes
by: Dale J. Morrison, et al.
Published: (2025)

Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT ‐1 to ‐4 trials
by: Domenica M. Rubino, et al.
Published: (2025)

Pre‐exercise protein intake is associated with reduced time in hypoglycaemia among adolescents with type 1 diabetes
by: Franklin R. Muntis, et al.
Published: (2024)

An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes
by: Angela X. Chen, et al.
Published: (2024)

Long‐term cost‐effectiveness of tirzepatide for individuals with type 2 diabetes and comorbid obesity
by: Man Tang, et al.
Published: (2025)

Liver fibrosis and liver stiffness in patients with obesity and type 1 diabetes
by: Ebaa Al‐Ozairi, et al.
Published: (2024)

Overweight or obesity, weight variability and the risk of retinopathy in type 1 diabetes
by: Thomas Nyström, et al.
Published: (2024)

Impact of caloric restriction on diabetes remission in Korean adults with obesity (CREDO‐K study)
by: Mee Kyoung Kim, et al.
Published: (2025)